Novavax to Participate in World Vaccine Congress Europe - il Centro Tirreno
Il sito "il Centro Tirreno.it" utilizza cookie tecnici o assimiliati e cookie di profilazione di terze parti in forma aggregata a scopi pubblicitari e per rendere più agevole la navigazione, garantire la fruizione dei servizi, se vuoi saperne di più leggi l'informativa estesa, se decidi di continuare la navigazione consideriamo che accetti il loro uso.
28
Dom, Nov

Novavax to Participate in World Vaccine Congress Europe

Immediapress
Typography
  • Smaller Small Medium Big Bigger
  • Default Helvetica Segoe Georgia Times

GAITHERSBURG, Md., Oct. 15, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that Vivek Shinde, M.D., Vice President, Clinical Development, will deliver a presentation during the World Vaccine

Congress Europe 2021. A topic of discussion will be Novavax' COVID-NanoFlu™ Combination Vaccine, which combines the company's recombinant nanoparticle protein-based COVID-19 and NanoFlu™ vaccine candidates with Matrix-M™ adjuvant in a single formulation. 

Session details are as follows: 

For more information or to register, visit the Congress website.   

About NovavaxNovavax, Inc. (Nasdaq: NVAX) is a biotechnology company that promotes improved health globally through the discovery, development and commercialization of innovative vaccines to prevent serious infectious diseases. The company's proprietary recombinant technology platform combines the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles designed to address urgent global health needs. Novavax is conducting late-stage clinical trials for NVX-CoV2373, its vaccine candidate against SARS-CoV-2, the virus that causes COVID-19. NanoFlu™, its quadrivalent influenza nanoparticle vaccine, met all primary objectives in its pivotal Phase 3 clinical trial in older adults. Both vaccine candidates incorporate Novavax' proprietary saponin-based Matrix-M™ adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies.  

For more information, visit www.novavax.com and connect with us on Twitter and LinkedIn. 

Contacts: 

InvestorsNovavax, Inc. Erika Schultz | Questo indirizzo email è protetto dagli spambots. È necessario abilitare JavaScript per vederlo.  

Solebury TroutAlexandra Roy | Questo indirizzo email è protetto dagli spambots. È necessario abilitare JavaScript per vederlo.  

MediaAli Chartan | 240-720-7804Laura Keenan Lindsey | 202-709-7521 Questo indirizzo email è protetto dagli spambots. È necessario abilitare JavaScript per vederlo.  

Logo - https://mma.prnewswire.com/media/1506866/Novavax_High_Res_Logo.jpg